ASPIRIN 81 MG Drug Interactions
Also known as: Aspirin Enteric Coated
ASPIRIN 81 MG (brand name: Aspirin Enteric Coated) is a NSAIDs. Use(s) for the temporary relief of minor aches and pain or as recommended by your doctor. Because of its delayed action, this product will not provide fast relief of headaches or other symptoms needing immediate relief.ASPIRIN 81 MG has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with aspirin 81mg significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided unless specifically directed and closely monitored by your doctor.
Mechanism
Naproxen, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Aspirin 81mg is an antiplatelet agent that irreversibly inhibits COX-1, preventing thromboxane A2 formation and platelet aggregation. The concurrent use of both drugs results in additive antiplatelet effects and increased gastrointestinal mucosal damage, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding, which can manifest as ulcers, melena, hematemesis, or even life-threatening hemorrhage. The risk of major gastrointestinal bleeding is estimated to be 3-5 times higher with this combination compared to either drug alone. Other bleeding risks include bruising, epistaxis, and prolonged bleeding time. This combination should generally be avoided. If concurrent use is absolutely necessary, it must be under strict medical supervision, with the lowest effective doses for the shortest duration. Monitor closely for signs of bleeding (e.g., black stools, vomiting blood, unusual bruising). Consider gastroprotective agents (e.g., proton pump inhibitors) if the combination is unavoidable. Alternative pain relief options that do not affect platelet function (e.g., acetaminophen) should be considered instead of naproxen.
Combining Etodolac, an NSAID, with Aspirin 81mg significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided unless specifically directed and closely monitored by your doctor.
Mechanism
Both Etodolac and Aspirin inhibit platelet aggregation, Etodolac through non-selective COX inhibition and Aspirin through irreversible COX-1 inhibition. This dual antiplatelet effect leads to an additive impairment of hemostasis. Additionally, NSAIDs can directly irritate the gastrointestinal mucosa, further increasing bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis). This can manifest as easy bruising, nosebleeds, or more severe internal bleeding, which may require hospitalization or blood transfusions. The risk of serious GI bleeding with this combination is significantly elevated compared to either drug alone. This combination should generally be avoided. If both drugs are deemed absolutely necessary, the patient must be closely monitored for signs of bleeding, and a proton pump inhibitor (PPI) should be co-prescribed to reduce GI bleeding risk. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. The lowest effective dose for the shortest duration should be used if continuation is unavoidable.
Taking multiple forms of aspirin, such as regular aspirin and aspirin 81 mg, at the same time can significantly increase your risk of bleeding, including serious stomach bleeding.
Mechanism
Both regular aspirin and aspirin 81 mg contain the same active ingredient, aspirin. Aspirin inhibits platelet aggregation irreversibly and also has NSAID properties. Taking both products concurrently leads to an additive antiplatelet effect and increased gastrointestinal irritation, significantly elevating the risk of bleeding.
Clinical Management
The primary clinical effect is an increased risk of bleeding, particularly gastrointestinal bleeding (e.g., stomach ulcers, hemorrhage), which can be severe and life-threatening. Symptoms may include black, tarry stools, vomiting blood, or unusual bruising. The risk of GI bleeding can be 3-15 times higher when NSAIDs are combined with other antiplatelets/anticoagulants, and this scenario represents an overdose of aspirin's antiplatelet effect. Patients should be advised to avoid taking multiple aspirin-containing products simultaneously. If aspirin is prescribed for antiplatelet therapy (e.g., 81 mg), other NSAIDs or aspirin products should be avoided unless specifically directed by a physician. Monitor for signs of bleeding and consider gastroprotective agents if high-dose aspirin is unavoidable.
Combining ibuprofen with aspirin 81 mg can significantly increase your risk of bleeding, especially in the stomach or intestines. It's important to discuss this with your doctor before taking both medications.
Mechanism
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Aspirin 81 mg also inhibits platelet aggregation, primarily through irreversible inhibition of COX-1. The concurrent use of these agents results in an additive antiplatelet effect and increased gastrointestinal mucosal damage, synergistically elevating bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can range from mild symptoms to life-threatening hemorrhage. This combination can lead to peptic ulcers, melena, hematemesis, or even hemorrhagic stroke. The risk of serious GI bleeding is significantly elevated, potentially 3-5 times higher than with either drug alone. Concurrent use of ibuprofen and aspirin 81 mg should generally be avoided due to the high bleeding risk. If pain relief is needed while on aspirin, acetaminophen is a safer alternative. If NSAID use is unavoidable, consider a COX-2 selective NSAID or a proton pump inhibitor (PPI) for gastroprotection, and monitor closely for signs of bleeding. Patients should be educated to report any signs of bleeding immediately.
Combining indomethacin with aspirin 81 mg significantly increases your risk of bleeding, particularly in the stomach and intestines. This combination should generally be avoided.
Mechanism
Both indomethacin (an NSAID) and aspirin (an antiplatelet) inhibit platelet aggregation, though through different mechanisms. Indomethacin reversibly inhibits cyclooxygenase (COX) enzymes, reducing thromboxane A2 production, while aspirin irreversibly inhibits COX-1. Their combined antiplatelet effects are additive, leading to a synergistic increase in bleeding tendency.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), which can be severe and life-threatening. The risk of serious upper gastrointestinal bleeding can be increased by 3 to 15 times compared to using either drug alone. Other bleeding events like epistaxis or bruising may also be more common. This combination should generally be avoided due to the high bleeding risk. If both anti-inflammatory and antiplatelet effects are absolutely necessary, consider alternative NSAIDs with lower GI risk (e.g., celecoxib if cardiovascular risk allows) or alternative pain management strategies. Close monitoring for signs of bleeding (e.g., black tarry stools, coffee-ground vomit, unexplained bruising) is crucial if co-administration is unavoidable.
Combining celecoxib with low-dose aspirin significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided unless specifically recommended and closely monitored by your doctor.
Mechanism
Celecoxib, a COX-2 selective NSAID, inhibits prostaglandin synthesis which can impair gastric mucosal protection. Aspirin, even at low doses, irreversibly inhibits platelet aggregation via COX-1 inhibition. The additive antiplatelet effect of aspirin combined with the gastrointestinal mucosal damage from celecoxib substantially elevates bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage). Symptoms may include black, tarry stools, vomiting blood, or unusual bruising. The risk of serious GI bleeding can be several-fold higher compared to either drug alone. This combination should be avoided if possible. If concomitant therapy is deemed essential, use the lowest effective doses for the shortest duration, and consider gastroprotective agents (e.g., proton pump inhibitors). Patients must be closely monitored for signs of bleeding, and alternatives to celecoxib should be explored.
Combining piroxicam (an anti-inflammatory pain reliever) with aspirin 81mg (a blood thinner) significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Piroxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, leading to impaired platelet function and damage to the gastrointestinal mucosa. Aspirin 81mg, even at low doses, irreversibly inhibits platelet aggregation. The combined antiplatelet effects and gastrointestinal irritation from both drugs create an additive risk for bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., stomach ulcers, melena, hematemesis). This combination can also increase the risk of other bleeding events such as epistaxis, bruising, or prolonged bleeding from cuts. The risk of serious GI bleeding can be 3 to 15 times higher than with either drug alone. This combination should generally be avoided due to the high bleeding risk. If both anti-inflammatory and antiplatelet effects are absolutely necessary, consider alternative NSAIDs with a lower GI risk (e.g., celecoxib, if appropriate, with a proton pump inhibitor) or alternative pain management strategies. Closely monitor for any signs of bleeding (e.g., black/tarry stools, vomiting blood, unusual bruising).
Combining meloxicam with aspirin 81 mg significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided unless specifically recommended and closely monitored by your doctor.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Aspirin 81 mg is an antiplatelet agent that irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, preventing thromboxane A2 formation and thus platelet aggregation. The combined antiplatelet effects and gastrointestinal mucosal damage from both drugs lead to an additive increase in bleeding risk.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage, perforation), but also other sites like bruising or epistaxis. The risk of serious GI bleeding can be several times higher compared to either drug alone. Symptoms may include black, tarry stools, vomiting blood, or severe abdominal pain. This combination should generally be avoided. If both agents are deemed absolutely necessary, the patient must be closely monitored for signs of bleeding, and a proton pump inhibitor (PPI) should be co-prescribed to reduce gastrointestinal risk. Consider alternative pain management strategies that do not involve NSAIDs, or use the lowest effective dose of meloxicam for the shortest duration possible.
Combining diclofenac with low-dose aspirin significantly increases your risk of serious bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair gastric mucosal protection and inhibit platelet aggregation. Aspirin 81 mg, an antiplatelet agent, irreversibly inhibits cyclooxygenase-1 (COX-1), leading to reduced thromboxane A2 production and prolonged platelet inhibition. The concurrent use of these drugs results in additive antiplatelet effects and increased gastrointestinal toxicity.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage) and other serious bleeding events. The risk of major gastrointestinal bleeding can be 3-15 times higher when NSAIDs are combined with antiplatelets compared to either drug alone, with a reported incidence of 2-4% per year for serious GI events. This combination should be avoided if possible. If concomitant therapy is unavoidable and the cardiovascular benefit outweighs the bleeding risk, consider prescribing a proton pump inhibitor (PPI) for gastroprotection. Closely monitor for signs of bleeding (e.g., black/tarry stools, unusual bruising, fatigue) and anemia. Alternative pain management strategies or NSAIDs with lower GI risk (e.g., celecoxib with PPI) may be considered, but still require caution.
Combining ketorolac with aspirin significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided due to the high risk.
Mechanism
Ketorolac, a non-selective NSAID, inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Aspirin 81mg also irreversibly inhibits COX-1, leading to reduced thromboxane A2 production and antiplatelet effects. The concurrent use of two agents with antiplatelet activity creates an additive effect, profoundly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, including gastrointestinal hemorrhage, peptic ulcers, and intracranial bleeding. The risk of major gastrointestinal bleeding can be several-fold higher compared to either drug alone, potentially leading to hospitalization, transfusions, or even death. This combination should be avoided if possible. If concomitant use is absolutely necessary, it should be done with extreme caution, close monitoring for signs of bleeding (e.g., black stools, easy bruising, unusual fatigue), and for the shortest duration possible. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen. Proton pump inhibitor prophylaxis may be considered if unavoidable.
For complete prescribing information:
View full ASPIRIN 81 MG monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.